July 31st, 2018

// ProMIS Neurosciences Issues White Paper Entitled ‘State of the Art at AAIC 2018’

ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'



Key conference theme: targeting toxic amyloid-beta oligomers offers renewed hope for treatment of Alzheimer's disease

TORONTO and CAMBRIDGE, MA, July 31, 2018 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of  antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced it has issued a white paper entitled 'State of the Art at AAIC 2018'.

At this year's Alzheimer's Association International Conference (AAIC), the causative role of  amyloid-beta oligomers (AβO) in the development and progression of Alzheimer's disease (AD) and the importance of neutralizing AβO toxicity represented a common theme across multiple oral presentations and posters. These included details of the recent positive Phase 2 clinical results obtained with BAN2401 by Eisai/Biogen showing a dose-dependent reduction in cognitive decline compared to placebo at 12 and 18 months.

"Overall, the BAN2401 results provide strong support for targeting of AβO as a therapeutic strategy for AD. However, the encouraging results reported leave room for improvement, due to the brain swelling (ARIA) associated with plaque binding in the higher BAN2401 dose groups", stated Dr. Elliot Goldstein, ProMIS President and CEO.
"As outlined in our poster presentation at the AAIC, humanized PMN310 shows unrivaled selectivity for native toxic AβO derived from human AD brains, with no off-target binding to Aβ monomers or plaque. We believe the oligomer selectivity of PMN310 supports a potential best in class product profile compared to other therapeutic antibodies currently showing promising results in clinical trials."

Another topic of high interest centered around advancements in the use of biomarkers driven by the convergence of emerging results from several large longitudinal studies together with recent FDA guidance encouraging the use of cerebrospinal fluid (CSF) and imaging biomarkers in clinical testing.

ProMIS' clinical candidate, humanized PMN310, is on track to enter Phase 1 clinical testing in the second half of 2019 and will include biomarker assessment as an integral part of the study design.

ProMIS white paper, entitled 'State of the Art at AAIC 2018' can be found on the ProMIS website, by clicking on the link below:

ProMIS AAIC poster presentation, entitled 'Humanized PMN310 shows enhanced therapeutic potential by binding toxic low molecular weight Aβ oligomers while avoiding ARIA-related binding to Aβ deposits in AD patient brains' can be found on the ProMIS website, by clicking on the link below:

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing antibody therapeutics targeting toxic oligomers implicated in the development of  neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company's website at: www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain "forward-looking statements" within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects", "plans", "anticipates",  believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions, or that events or conditions "will", "would", "may", "can", "could" or "should" occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.

SOURCE ProMIS Neurosciences Inc.

For further information:

Media inquiries for ProMIS, David Schull, RussoPartners/LLC, David.Schull@russopartnersllc.com, Tel. 858 717-2310; Investor Relations inquiries for ProMIS, Alpine Equity Advisors, Nicholas Rigopulos, President, nick@alpineequityadv.com, Tel. 617 901-0785; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.goldstein@promisneurosciences.com


Sign Up and get a free 7 day Train it Right HIIT Program!